Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biohaven Ltd.BHVN · Entity 4379 | SVP, Clinical Operations | September 15, 2026 | September 17, 2026 |
| Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269 | SVP, Clinical Operations | October 03, 2022 | October 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biohaven Ltd.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.34 · Expires 2036-09-15 | IndirectBy Son | 1,000 |
Reported balance
After 2026-09-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 1,000 · Balance 1,000 F1: The shares underlying this option vest in four equal installments on September 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's son's continuous service with the Issuer at each vesting date. F2: Represents a stock option granted to the Reporting Person's son in connection with the commencement of his employment with the Issuer. The Reporting Person disclaims beneficial ownership of all securities held by her son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in four equal installments on September 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's son's continuous service with the Issuer at each vesting date.
F2: Represents a stock option granted to the Reporting Person's son in connection with the commencement of his employment with the Issuer. The Reporting Person disclaims beneficial ownership of all securities held by her son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Biohaven Pharmaceutical Holding Co Ltd.
Report date October 03, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 11,653 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-03 · Disposition to issuer · Disposed 13,000 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-03 · Disposition to issuer · Disposed 7,500 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-03 · Disposition to issuer · Disposed 3,750 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.69 · Expires 2032-01-07 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-03 · Disposition to issuer · Disposed 775 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.69 · Expires 2032-01-07 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-03 · Disposition to issuer · Disposed 25,225 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.32 · Expires 2031-01-06 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-03 · Disposition to issuer · Disposed 2,398 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.32 · Expires 2031-01-06 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-10-03 · Disposition to issuer · Disposed 27,602 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.99 · Expires 2029-11-25 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-10-03 · Disposition to issuer · Disposed 28,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.60 · Expires 2029-03-22 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-10-03 · Disposition to issuer · Disposed 6,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2028-11-20 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-10-03 · Disposition to issuer · Disposed 61,916 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2028-11-20 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-10-03 · Disposition to issuer · Disposed 3,084 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.28 · Expires 2027-12-06 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2022-10-03 · Disposition to issuer · Disposed 590 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.28 · Expires 2027-12-06 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2022-10-03 · Disposition to issuer · Disposed 41,432 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.62 · Expires 2027-09-04 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2022-10-03 · Disposition to issuer · Disposed 9,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 · Expires 2027-04-05 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2022-10-03 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2020 Filed Jan 10, 2020 19:46 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 590 | $0.00 Strike: $20.79 | $0.00 |
DisclosureSEC source: 0001562180-20-000345 · primarydocument.xml · derivative · entry 4 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,022 Underlying: Common Shares · 590 shares Expires 2027-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing a right to purchase a total of 1,180 shares, was granted on December 7, 2017, and vested in four equal installments on December 7, 2018, 2019, 2020 and 2021. Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 19:46 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $37.54 | $0.00 |
DisclosureSEC source: 0001562180-20-000345 · primarydocument.xml · derivative · entry 3 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 1,000 shares Expires 2027-09-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, representing a right to purchase a total of 10,000 shares, was granted on September 5, 2017, and vested in four equal installments on September 5, 2018, 2019, 2020 and 2021. Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 19:46 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 590 | $20.79 | $12,266.10 |
DisclosureSEC source: 0001562180-20-000345 · primarydocument.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 19:46 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 1,000 | $37.54 | $37,540.00 |
DisclosureSEC source: 0001562180-20-000345 · primarydocument.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:40 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionRestricted Share Unit Award · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001689813-19-000131 · wf-form4_157689601303289.xml · derivative · entry 3 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Shares · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F2 · price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F3 · derivative.exercise_date: The reporting person was granted 15,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:40 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Tax withholdingCommon Shares | 1,701 | $52.13 | $88,673.13 |
DisclosureSEC source: 0001689813-19-000131 · wf-form4_157689601303289.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,049 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:40 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001689813-19-000131 · wf-form4_157689601303289.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:31 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantRestricted Share Unit Award · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001689813-19-000112 · wf-form4_157490827071293.xml · derivative · entry 2 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2022-11-24 F2 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F2 · price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F3 · derivative.exercise_date: The reporting person was granted 15,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:31 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantEmployee Stock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $57.40 | $0.00 |
DisclosureSEC source: 0001689813-19-000112 · wf-form4_157490827071293.xml · derivative · entry 1 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Shares · 28,000 shares Expires 2029-11-24 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on November 25, 2019, 2020, 2021 and 2022, subject to the optionholder's continuous service with the issuer at each vesting date. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:36 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,065 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001689813-19-000096 · wf-form4_157447655027980.xml · derivative · entry 6 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 21,065 shares Expires 2024-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 62,500 shares, was granted on November 26, 2014, and vested in four equal installments on November 26, 2014, 2015, 2016 and 2017. The optionholder previously exercised the option with respect to an aggregate of 37,500 shares during 2017 and 2018. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:36 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 21,065 | $53.04 | $1,117,205.45 |
DisclosureSEC source: 0001689813-19-000096 · wf-form4_157447655027980.xml · nonDerivative · entry 4 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 - $53.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:36 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 21,065 | $0.61 | $12,849.65 |
DisclosureSEC source: 0001689813-19-000096 · wf-form4_157447655027980.xml · nonDerivative · entry 3 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:36 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,935 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001689813-19-000096 · wf-form4_157447655027980.xml · derivative · entry 5 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,065 Underlying: Common Shares · 3,935 shares Expires 2024-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 62,500 shares, was granted on November 26, 2014, and vested in four equal installments on November 26, 2014, 2015, 2016 and 2017. The optionholder previously exercised the option with respect to an aggregate of 37,500 shares during 2017 and 2018. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:36 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 3,935 | $53.03 | $208,665.18 |
DisclosureSEC source: 0001689813-19-000096 · wf-form4_157447655027980.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 - $53.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:36 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 3,935 | $0.61 | $2,400.35 |
DisclosureSEC source: 0001689813-19-000096 · wf-form4_157447655027980.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 17:35 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $50.85 | $0.00 |
DisclosureSEC source: 0001209191-19-039783 · doc4.xml · derivative · entry 1 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Shares · 6,000 shares Expires 2029-03-22 F1 · derivative.exercise_price: Represents the vesting of a previously granted employee stock option upon the satisfaction of the performance-based vesting conditions of the award. F1 · date: Represents the vesting of a previously granted employee stock option upon the satisfaction of the performance-based vesting conditions of the award. F1 · shares: Represents the vesting of a previously granted employee stock option upon the satisfaction of the performance-based vesting conditions of the award. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 20, 2018 Filed Feb 14, 2019 16:40 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $32.42 | $0.00 |
DisclosureSEC source: 0001209191-19-010214 · doc5.xml · derivative · entry 1 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires 2028-11-19 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the reporting person's continuous service with the issuer at each vesting date. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 16:43 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-18-038584 · doc4.xml · derivative · entry 3 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 12,500 shares Expires 2024-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 16:43 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 12,500 | $40.02 | $500,250.00 |
DisclosureSEC source: 0001209191-18-038584 · doc4.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 - $40.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 16:43 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 12,500 | $0.61 | $7,625.00 |
DisclosureSEC source: 0001209191-18-038584 · doc4.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 16:31 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-18-016467 · doc4.xml · derivative · entry 4 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Shares · 5,000 shares Expires 2024-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 16:31 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 2,200 | $33.44 | $73,568.00 |
DisclosureSEC source: 0001209191-18-016467 · doc4.xml · nonDerivative · entry 3 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.09 - $33.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 16:31 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 2,800 | $32.42 | $90,776.00 |
DisclosureSEC source: 0001209191-18-016467 · doc4.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.01 - $32.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 16:31 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 5,000 | $0.61 | $3,050.00 |
DisclosureSEC source: 0001209191-18-016467 · doc4.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 18:18 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-18-007147 · doc4.xml · derivative · entry 5 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Shares · 5,000 shares Expires 2024-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 18:18 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 300 | $33.99 | $10,197.00 |
DisclosureSEC source: 0001209191-18-007147 · doc4.xml · nonDerivative · entry 4 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.98 - $33.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 18:18 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 1,348 | $33.53 | $45,198.44 |
DisclosureSEC source: 0001209191-18-007147 · doc4.xml · nonDerivative · entry 3 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.96 - $33.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 18:18 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 3,352 | $32.37 | $108,504.24 |
DisclosureSEC source: 0001209191-18-007147 · doc4.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,648 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.95 - $32.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 18:18 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 5,000 | $0.61 | $3,050.00 |
DisclosureSEC source: 0001209191-18-007147 · doc4.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 17:28 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-18-001156 · doc4.xml · derivative · entry 3 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Shares · 5,000 shares Expires 2024-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 17:28 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 5,000 | $27.60 | $138,000.00 |
DisclosureSEC source: 0001209191-18-001156 · doc4.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.27 - $28.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 17:28 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 5,000 | $0.61 | $3,050.00 |
DisclosureSEC source: 0001209191-18-001156 · doc4.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2017 Filed Dec 11, 2017 17:36 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantEmployee Stock Option (Right to Buy) · Derivative | 42,612 | $0.00 Strike: $20.79 | $0.00 |
DisclosureSEC source: 0001209191-17-065065 · doc4.xml · derivative · entry 1 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,612 Underlying: Common Shares · 42,612 shares Expires 2027-12-06 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on December 7, 2018, 2019, 2020 and 2021, subject to the reporting person's continuous service with the issuer at each vesting date. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 16:02 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-17-063860 · doc4.xml · derivative · entry 5 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Shares · 5,000 shares Expires 2024-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares underlying this option were fully vested as of November 26, 2017. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 16:02 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 200 | $23.04 | $4,608.00 |
DisclosureSEC source: 0001209191-17-063860 · doc4.xml · nonDerivative · entry 4 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.01 - $23.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 16:02 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 2,798 | $22.42 | $62,731.16 |
DisclosureSEC source: 0001209191-17-063860 · doc4.xml · nonDerivative · entry 3 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.93 - $22.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 16:02 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 2,002 | $21.29 | $42,622.58 |
DisclosureSEC source: 0001209191-17-063860 · doc4.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,998 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.88 - $21.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 16:02 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 5,000 | $0.61 | $3,050.00 |
DisclosureSEC source: 0001209191-17-063860 · doc4.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 17:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-17-058953 · doc4.xml · derivative · entry 4 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Shares · 5,000 shares Expires 2024-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this option vested as to 25% of the shares on November 26, 2014, with the remainder vesting in 3 equal increments on the anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 17:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 1,414 | $29.65 | $41,925.10 |
DisclosureSEC source: 0001209191-17-058953 · doc4.xml · nonDerivative · entry 3 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.48 - $29.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 17:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 3,586 | $29.13 | $104,460.18 |
DisclosureSEC source: 0001209191-17-058953 · doc4.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,414 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.48 - $29.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 17:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 5,000 | $0.61 | $3,050.00 |
DisclosureSEC source: 0001209191-17-058953 · doc4.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2017 Filed Sep 12, 2017 18:12 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $37.54 | $0.00 |
DisclosureSEC source: 0001209191-17-052476 · doc4.xml · derivative · entry 1 Gentile Kimberly · CIK 0001704186 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2027-09-04 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on September 5, 2018, 2019, 2020 and 2021, subject to the reporting person's continuous service with the issuer at each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.